Opiate-mediated inhibition of the release of cholecystokinin and substance P, but not neurotensin from cat hypothalamic slices

Stimulation of δ-Opioid Receptors Reduces the In Vivo Binding of the Cholecystokinin (CCK)-B-Selective Agonist [3H]pBC 264: Evidence for a Physiological Regulation of CCKergic Systems by Endogenous Enkephalins

Cholecystokinin (CCK) and enkephalins appear to be colocalized in several brain structures, and a physiological interaction between these peptides has been suggested by a large number of pharmacological studies. In this work we have shown, by in vivo binding experiments, that the endogenous enkephalins, protected from degrading enzymes by mixed inhibitors such as kelatorphan and N-[(R,S)-2-benzyl-3-[(S)-2-amino-4-methylthiobutyldithio]-1-oxo pro pyl]- L-phenylalanine benzyl ester (RB 101), a systemically active prodrug, modulate CCK release in mouse brain, leading to an overall increase in the extracellular levels of CCK. This was quantified by measuring the effects of both inhibitors on the in vivo binding of [3H]propionyl-Tyr(SO3H)-gNle-mGly-Trp-(N-Me)Nle-Asp-Phe-NH2 ([3H]pBC 264), a selective and highly potent CCK-B agonist. Thus, intracerebroventricular injection of kelatorphan produced a dose-dependent inhibition of the in vivo binding of [3H]pBC 264 with a maximal effect (40%) at 50 nmol. A similar response was observed after intravenous injection of RB 101 (40 mg/kg). The specific binding of [3H]pBC 264 was also inhibited (25%) by intravenous injection of the selective delta-opioid agonist H-Tyr-D-Cys(StBu)-Gly-Phe-Leu-Thr(OtBu)-OH (BUBUC; 2 mg/kg) but not by the mu-agonist H-Tyr-D-Ala-Gly-(N-Me)Phe-Gly-ol (5 mg/kg), suggesting a preferential involvement of delta-opioid receptors in the modulation of CCK release. This was confirmed by using the selective delta-opioid antagonist naltrindole, which prevented the inhibitory effects of BUBUC and of enkephalin-degrading enzyme inhibitors on [3H]pBC 264 binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Estrogen and endogenous opioids regulate CCK in reproductive circuits

This review focuses on the interaction of estrogen with the cholecystokinin (CCK) and endogenous opioid peptide systems in the medial preoptic nucleus, and how these interactions result in alterations of a stereotypic female reproductive behavior--lordosis. The medial preoptic nucleus is an integral part of a circuit controlling lordosis that extends from the limbic system through the hypothalamus. Estrogen alters the integration of sensory information in the circuit that results in the display of sexually receptive behavior. Estrogen determines the activity of CCK and endogenous opioid peptide systems through regulation of expression, release and interaction with specific receptors. Studies of each system individually have indicated that they are pivotal to the expression of lordosis. Recent studies demonstrate an estrogen-dependent interaction between endogenous opioid and CCK systems that control reproductive behavior.

The effects of glutamate receptor agonists on neurotensin release using in vivo microdialysis

In the present study, extracellular concentrations of neurotensin were measured from the striatum, nucleus accumbens and the medial prefrontal cortex in the awake, freely moving rat. Using a highly sensitive solid phase radioimmunoassay, basal concentrations of neurotensin were 2-5 pg/sample. In each region, glutamate receptor agonists, N-methyl-D-aspartate (NMDA) and kainic acid, increased neurotensin release 2-3-fold. Preincubation with the Na(+) channel blocker tetrodotoxin abolished the glutamate receptor agonist-induced increases except in the striatum following kainic acid infusion. These findings indicate that activation of glutamate receptors may indirectly stimulate neurotensin release.

Evidence for co-existence of CCK-8 and GnRH in neurons of the mesencephalic tegmentum in the chameleon

A double-label immunofluorescence technique was used to demonstrate the co-localization of cholecystokinin-8 (CCK-8) and gonadotrophin-releasing hormone (GnRH) in individual neurons and processes of the chameleon brain. Co-localization was limited to a small population of cells in the dorsomedial tegmentum; in other regions of the brain, neurons were observed to be either CCK-8-immunopositive or GnRH-immunopositive but never both. However, double-labeled fibers and terminals were found to be distributed at a low density throughout the thalamus, the medial hypothalamus, the tegmentum and the spinal cord. These data provide the first indication for the co-localization of CCK-8 and GnRH, whose functional significance remains to be established. ON

Opiate receptors modulate estrogen-induced cholecystokinin and tachykinin but not enkephalin messenger RNA levels in the limbic system and hypothalamus

Cholecystokinin, substance P and methionine enkephalin all regulate the display of reproductive behaviour. Their expression is exquisitely regulated by estrogen in the limbic-hypothalamic circuit, a circuit that regulates the display of estrogen-sensitive female reproductive behavior. Relatively little is known, however, about the interaction of endogenous opioid peptides with cholecystokinin and substance P in the limbic-hypothalamic circuit. Opiates antagonize the release of cholecystokinin and substance P in the hypothalamus and periaqueductal gray and stimulate cholecystokinin messenger RNA levels in the amygdala. To determine the effect of endogenous opioid input on estrogen-induced cholecystokinin, enkephalin and substance P expression, in situ hybridization histochemistry was used to examine estrogen-induced messenger RNA levels of these neuropeptides in specific nuclei of the limbic system and hypothalamus in the presence of opiate receptor antagonists. Estrogen treatment of ovariectomized rats significantly elevated cholecystokinin messenger RNA levels in the central portion of the medial preoptic nucleus, the encapsulated portion of the bed nucleus of the stria terminalis and the posterodorsal medial amygdala, as well as increased preproenkephalin and preprotachykinin messenger RNA levels in the ventromedial hypothalamic nucleus and the posterodorsal medial amygdala. The universal opiate receptor antagonist naltrexone and the delta-opiate receptor antagonist naltrindole each potentiated the estrogen-induced increase and elevated cholecystokinin messenger RNA levels an additional 1.9- to 2.8-fold depending on the nucleus examined, but had no effect on the estrogen-induced expression of either preproenkephalin or preprotachykinin messenger RNA. beta-Funaltrexamine, a mu-opiate receptor antagonist, had no effect on the medial preoptic or medial amygdaloid cholecystokinin messenger RNA levels or on the estrogen-induced expression of preproenkephalin messenger RNA but did cause a decrease in estrogen-induced cholecystokinin messenger RNA levels in the bed nucleus of the stria terminalis and a decrease in the preprotachykinin messenger RNA levels in the ventromedial hypothalamic nucleus. These results indicate that endogenous opioids, acting on the delta-opiate receptor within nuclei of the limbic-hypothalamic circuit, restrain the estrogen-induced increase of cholecystokinin messenger RNA expression. Activation of the mu-opiate receptor, however, may facilitate cholecystokinin messenger RNA expression in the bed nucleus of the stria terminalis and preprotachykinin messenger RNA expression in the ventromedial hypothalamic nucleus. Thus, endogenous opioid peptides may act in a site- and receptor-specific manner to modulate estrogen-induced neuropeptide levels in the limbic system and hypothalamus.

Effects of mu- and delta-opioid-receptor antagonists on the stimulus properties of cholecystokinin

Melton and Riley recently reported that the relatively selective mu-opioid-antagonist naloxone potentiated the stimulus properties of the gut peptide cholecystokinin (CCK). To assess whether such opioid potentiation is limited to activity at the mu-receptor subtype, in the present experiment the effects of the highly selective delta-antagonist naltrindole on CCK's stimulus properties were examined. Because in the initial report of naloxone's potentiation of CCK a relatively high, nonphysiologic dose of CCK (i.e., 13 micrograms/kg) was used as the training drug, in the current analysis subjects were trained to discriminate 5.6 micrograms/kg CCK from its vehicle and the assessments and comparisons of the effects of naloxone and naltrindole were based on this dose. Specifically, rats were administered 5.6 micrograms/kg CCK before saccharin-LiCl pairings and the CCK vehicle before saccharin alone. With such training, they rapidly acquired the drug discrimination, avoiding saccharin consumption when it was preceded by CCK and consuming the same saccharin solution when it was preceded by its vehicle. In subsequent generalization tests, doses of CCK that were ineffective in suppressing saccharin consumption (i.e., did not substitute for the training dose of CCK) did result in the suppression of saccharin consumption when combined with doses of the mu antagonist naloxone that alone had no effect on saccharin intake. On the other hand, the highly selective delta-opioid-receptor antagonist naltrindole was ineffective in potentiating the effects of CCK. Specifically, when naltrindole was combined with ineffective doses of CCK, subjects drank at control levels. The ability of naloxone to potentiate CCK's stimulus effects is consistent with a range of other demonstrations of the role of the mu-opioid-receptor subtype in CCK-opioid interactions, although the specific basis for the interaction remains unknown. Given recent findings on the effects of delta agonists and antagonists on CCK-induced activity, the failure of naltrindole to potentiate CCK's stimulus effects may be due to the absence of delta activity within this preparation, rather than the absence of delta mediation of CCK-opioid interactions in general.

Modulation by opioid peptides of mechanosensory pathways supplying the guinea-pig inferior mesenteric ganglion

1. Radioimmunological techniques were used in isolated guinea-pig inferior mesenteric ganglion (IMG)-colon preparations to determine whether opioid peptides and neurotensin8-13 (NT8-13), the C-terminal region of NT1-13 recognized by neurotensin receptors, modulate distension-induced release of substance P (SP)- and vasoactive intestinal polypeptide (VIP)-like immunoreactive (LI) material. 2. Colonic distension significantly increased the amount of SP- and VIP-LI material released in the ganglionic superfusate. A low-Ca2+ (0.1 mM), high-Mg2+ (15 mM) solution blocked their release. 3. In vivo capsaicin pretreatment abolished release of SP-LI material during colonic distension but had no significant effect on distension-induced release of VIP-LI material. 4. The addition of [Leu5]enkephalin, [Met5]enkephalin, PL017 (a mu-receptor agonist) and DPDPE (a delta-receptor agonist) to the ganglion side of a two-compartment chamber blocked distension-induced release of SP-LI material. The addition of naloxone and ICI-174,864 (a delta-receptor antagonist) to the ganglion compartment reversed the inhibitory effect of the mu- and delta-receptor agonists. 5. Addition of [Leu5]enkephalin and [Met5]enkephalin to the ganglion compartment had no significant effect on release of VIP-LI material during colonic distension. 6. Addition of NT8-13 to the ganglion compartment significantly increased in the amount of SP-LI material released during colonic distension but had no affect on distension-induced release of VIP-LI material. 7. The results suggest the hypothesis that under in vivo conditions, enkephalinergic nerves decrease and neurotensinergic nerves increase the release of SP from peripheral branches of primary afferent sensory nerves.

Release of calcitonin gene-related peptide in guinea pig inferior mesenteric ganglion

Neurons of the guinea pig IMG are surrounded by nerve fibers containing CGRP-like immunoreactivity (LI). The purpose of this study was to determine whether colonic distension releases CGRP-LI in the IMG and whether opioid peptides and neurotensin(8-13) [NT(8-13)] modulate its release. Colonic distension released CGRP-LI. Methionine-enkephalin acted through mu and/or delta receptors to block release. NT(8-13) had no effect on release of CGRP-LI. Capsaicin pretreatment reduced the content of CGRP-LI in the IMG by 37%. Colonic distension did not release CGRP-LI from capsaicin-insensitive fibers. The data suggest that colonic distension releases CGRP-LI material from capsaicin-sensitive nerves and that enkephalins modulate release of CGRP-LI.

An assessment of the interaction between cholecystokinin and the opiates within a drug discrimination procedure

Recently, cholecystokinin (CCK) has been reported to antagonize a variety of opiate-induced effects, including nociception, body shaking, thermoregulation, and locomotion. Consistent with these results, a number of CCK antagonists potentiate the opiates in a range of behavioral and physiological assessments. The present study further examined the interaction between CCK and the opiates within the conditioned taste aversion baseline of drug discrimination learning, a design that utilizes the stimulus properties of the drug to control consummatory behavior. Specifically, animals injected with CCK prior to saccharin-LiCl pairings and the CCK vehicle prior to saccharin alone rapidly acquired the CCK-vehicle discrimination, avoiding saccharin consumption following the administration of CCK and consuming the same saccharin solution following the vehicle. Although the stimulus properties of CCK did not generalize to either naloxone or diprenorphine, morphine blocked and naloxone potentiated CCK's stimulus effects. These data are thus consistent with a physiological (rather than a pharmacological) interaction between CCK and the opiates.

Release of cholecystokinin in the central nervous system

The octapeptide cholecystokinin (CCK) is one of the most abundant neuropeptides of the central nervous system. A number of features (for instance heterogeneity of the regional distribution, subcellular localization at the nerve terminal level, calcium-dependent release upon nervous tissue depolarization) support the candidacy of CCK as a neurotransmitter. The reported co-existence of CCK and dopamine in some meso-limbic neurons has led to speculation that the neuropeptide may interact with the catecholamine in neuropsychopathologies linked to dopamine dysfunctions, like schizophrenia. Data from the experimental animals have so far generated conflicting results. It should be noted that the interactions between CCK and dopamine, and, in particular, the effects of CCK and dopamine on each other release, both in vitro and in vivo, have been poorly investigated and would require special attention. Evidence is accumulating that CCK may participate in the expression of anxiety. Indeed antagonists at the central CCK receptors exhibit anxiolytic activity in the laboratory animal. An interesting linkage appears to exist in the brain between 5-hydroxytryptamine (5-HT) and CCK. Activation of 5-HT3 receptors was found to increase CCK release from rat cortical or nucleus accumbens synaptosomes. Interestingly, antagonists at 5-HT3 receptors appear to possess anxiolytic activity. Recent studies carried out in conscious unrestrained rats show that the calcium-dependent, tetrodotoxin-sensitive release of CCK-like immunoreactivity evoked in the rat frontal cortex by veratrine infusion can be inhibited by submicromolar concentrations of 5-HT3 receptor antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Involvement of opioid mechanisms in peripheral motor control of detrusor muscle

Isometric recordings of mechanical activity in muscle strips from rat and human detrusor were performed and the effect of mu- and delta-opioid receptor stimulation and blockade on detrusor contraction induced by electrical field stimulation was tested. Stimulation of the opioid mu-receptor with morphine (10(-13)-10(-4) M) and DAGO (10(-13)-10(-6) M) had no significant effect on electrical field stimulation except at one concentration of morphine (10(-6) M). Naloxone (10(-10)-10(-5) M) caused a significant facilitation of the electrical field stimulation-induced contraction, which was counteracted by morphine (10(-8) M) and the delta-agonist DPDPE (10(-8) M) in both rat and human detrusor. Addition of atropine (10(-6) M) or hexamethonium chloride (10(-6) M) or spantide (10(-6) M) did not alter the facilitating effect of naloxone in the rat detrusor. Hexamethonium (10(-5) M) decreased the facilitating effect of naloxone on electrical field stimulation-induced contractions in the human detrusor, indicating involvement of ganglionic mechanisms. In human detrusor about 15% of the contractile response was found to be atropine-resistant (10(-6) M) and one third of this was found to be resistant to tetrodotoxin (1.5 x 10(-6) M). The atropine resistant-response in human detrusor was facilitated by naloxone to the same extent as the atropine-sensitive part. Adrenergic blockade per se, achieved with phentolamine mesylate (10(-6) M) and propranolol (10(-6) M), caused a significant facilitation of the electrical field stimulation-induced contraction in the rat detrusor but did not affect the facilitating effect of naloxone (10(-13)-10(-5) M).(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of chronic morphine on biliary tract responses to cholecystokinin-octapeptide in male guinea pigs

Opioid peptides share the spasmogenic action of acutely administered morphine on the sphincter of Oddi. In this study, gallbladder function was assessed following chronic opioid administration. Implantation of morphine pellets (400 mg) in male guinea pigs depressed cholecystokinin-octapeptide(CCK)-induced emptying of gallbladder bile (monitored via a duodenal cannula). Gallbladder muscle strips, isolated from the morphine treated animals, showed depressed contractile responses to CCK. This antagonism was non-specific and indirectly mediated, as ACh contractions were also depressed, whereas CCK-induced contractions of gallbladder strips from untreated animals were unaffected by direct exposure to morphine (3 x 10(-6)M). The depression of CCK stimulation of bile flow by chronic morphine administration in male guinea pigs suggests that chronic exposure to opioids can impede gallbladder emptying.

Influence of in situ neural isolation of jejunoileum on postprandial pancreatobiliary secretion and gastric emptying

Our aims were to examine the influence of neural isolation of the jejunoileum on postprandial pancreatobiliary secretion. In four dogs, duodenal perfusion and aspiration catheters were implanted, and serosal electrodes were placed along the proximal small bowel. Control studies of gastric emptying, output of bile acids and amylase, and plasma concentrations of peptide YY and neurotensin were performed on three occasions following ingestion of a 340-kcal mixed-nutrient liquid meal. The dogs then underwent our model of in situ jejunoileal neural isolation, and the meal studies were repeated. Neural isolation, when compared to control, did not affect either postprandial conversion of intestinal myoelectric activity to the "fed" pattern, gastric emptying (T1/2, X +/- SE of the liquid meal (74 +/- 6 vs 79 +/- 7 min; P greater than 0.05), or cumulative amylase output (373 +/- 59 vs 305 +/- 66 kU; P greater than 0.05). Neural isolation decreased cumulative postprandial bile acid output from 6.6 +/- 0.9 mM to 3.4 +/- 1.1 mM (P less than 0.05) and increased postprandial plasma concentrations of peptide YY and neurotensin. Our findings suggest that the jejunoileal denervation that accompanies the in situ neural isolation of the jejunoileum is not associated with changes in postprandial motility patterns, gastric emptying, or pancreatic amylase secretion. Loss of this innervation, however, may decrease postprandial output of bile acids and lead to a compensatory increase in the postprandial release of neurotensin and peptide YY.

Effects of substance P and vasoactive intestinal polypeptide on contractile activity and epithelial transport in the ferret jejunum

Previous studies in the ferret demonstrated that vagal nerve stimulation induced an atropine-resistant water secretion. Substance P and vasoactive intestinal polypeptide are possible mediators of this secretory response. The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium. Substance P caused an increase in jejunal motility, water secretion, and transmural potential difference. Cholinergic blockade did not affect the substance P-induced contractions, but did reduce the increase in transmural potential difference, suggesting an inhibition of water secretion. Vasoactive intestinal polypeptide abolished motor activity; however, it induced an increase in transmural potential difference that was atropine and tetrodotoxin resistant. By immunohistochemical methods, immunoreactive vasoactive intestinal polypeptide and immunoreactive substance P were localized to both nerve cell bodies and nerve fibers in the ferret intestine. Determination of intestinal concentrations of vasoactive intestinal polypeptide and substance P in the ferret showed concentrations of these two neuropeptides that were similar to those in human intestine and demonstrated much higher concentrations of these substances in the muscular layer than in the epithelial layer. Our data demonstrate that in the ferret substance P excites and vasoactive intestinal polypeptide inhibits jejunal motor activity. However, both peptides increase water secretion. Our results suggest that in response to vagal stimulation, neuronally released substance P or vasoactive intestinal polypeptide may participate in the atropine-resistant water secretion.

A model of jejunoileal in vivo neural isolation of the entire jejunoileum: transplantation and the effects on intestinal motility

The effects of intestinal transplantation on enteric physiology have not been well studied. Our aim was to determine the effect of jejunoileal transplantation on patterns of small intestinal motility. To avoid confounding effects of immune rejection or immunosuppression, we developed a model of autotransplantation in which all tissue connections to the entire jejunoileum were transected at the base of the mesentery except for the superior mesenteric artery and vein which were stripped meticulously of investing adventitia. After 3 weeks, motility was studied in eight dogs with intestinal electrodes during fasting, after meals of 50 and 500 g of liver, and during intravenous infusions of pentagastrin and cholecystokinin. During fasting, the characteristic inter-digestive migrating motor complex (MMC) was present in both the innervated duodenum and the "autotransplanted" jejunoileum; however, temporal coordination between the two regions was abolished. Feeding 50 g of liver abolished the MMC in the duodenum, but not in the jejunoileum; in contrast, 500 g of liver interrupted the MMC in both regions. Exogenous pentagastrin and cholecystokinin inhibited the MMC for the duration of the infusions. These findings suggest that extrinsic nerves and/or intrinsic (enteric) myoneural continuity do not initiate fasting motor patterns in the jejunoileum but do regulate the temporal coordination of motor patterns between segments of small intestine. Postprandial inhibition of the MMC is only in part mediated by neural factors. After transplantation, motility is abnormal; the overall effects on enteric physiology remain unknown.

Cholecystokinin interferes with the thermoregulatory effect of exogenous and endogenous opioids

Intraperitoneal (ip) injection of cholecystokinin octapeptide sulfate ester (CCK; 5, 10 and 50 micrograms/kg) reduced the hypothermic response to 8 mg/kg and 32 mg/kg systemic morphine in restrained and freely moving rats, respectively. The hyperthermia elicited by a subcutaneous (sc) injection of 8 mg/kg morphine to freely moving rats was not diminished by CCK pretreatment. CCK (5 micrograms/kp ip) completely prevented the restraint stress-induced hyperthermia. Naloxone (1 mg/gk sc) was effective in antagonizing both the hyperthermic and the hypothermic effects of morphine and the stress-induced emotional hyperthermia. These results support the hypothesis that CCK may contribute to regulation of the endogenous opioid system.

Neurotensin facilitates release of substance P in the guinea-pig inferior mesenteric ganglion

1. Intracellular, electrophysiological techniques were combined with radio-immunological, chromatographic and pharmacological techniques to determine if nerve terminals containing substance P mediated transient depolarizing responses of principal ganglion cells induced by neurotensin. Experiments were performed in vitro on guinea-pig inferior mesenteric ganglia. 2. In 61% of principal ganglion cells tested in normal ganglia, neurotensin caused a transient membrane depolarization. In ganglia which were removed from animals which had been pre-treated with capsaicin, transient responses to neurotensin were virtually abolished. 3. In normal ganglia, neurotensin increased the amplitude and duration of noncholinergic slow EPSPs evoked by electrical stimulation of the lumbar colonic nerve. Such increases were absent in ganglia obtained from animals pre-treated with capsaicin. 4. In guinea-pigs pre-treated with capsaicin, the content of substance P-like material was significantly reduced in inferior mesenteric and coeliac ganglia, dorsal root ganglia and lumbar spinal cord, compared to control animals. The content of substance P-like material in segments of distal colon was slightly reduced. The content of vasoactive intestinal polypeptide-, cholecystokinin- and bombesin-like material in the same tissues from animals pre-treated with capsaicin was not significantly different from control animals. 5. Chromatographic analysis using HPLC (high-performance liquid chromatography) techniques revealed that the material depleted from inferior mesenteric and coeliac ganglia, dorsal root ganglia and lumbar spinal cord by capsaicin pre-treatment co-eluted with synthetic substance P. 6. Electrical stimulation of the lumbar colonic nerve released substance P-like material from isolated inferior mesenteric ganglia as determined by radioimmunoassay of samples of superfusate. Exogenous administration of neurotensin caused a significant increase in the amount of substance P-like material released during nerve stimulation. 7. Transient depolarizing responses evoked by neurotensin were markedly attenuated when ganglion cells were postsynaptically desensitized to exogenously administered substance P. 8. Taken together, these findings suggest that transient depolarizations mediated by an indirect action of neurotensin and facilitation of electrically evoked non-cholinergic slow EPSPs by neurotensin involved presynaptic release of substance P from collateral nerve terminals of primary afferent nerve fibres in the inferior mesenteric ganglion. 9. It was suggested that under normal in vivo conditions, neurotensin or a C-terminal-related peptide contained in central preganglionic nerve endings might function as an excitatory neuromodulator to enhance the release of substance P from primary afferent nerve terminals thereby facilitating non-cholinergic peripheral afferent synaptic input to prevertebral ganglion cells.

Short-chain fatty acids stimulate ileal motility in humans

We tested the hypothesis that short-chain fatty acids (SCFAs) and distention would stimulate ileal motility in humans. Intraluminal pressures in the ileocolonic region were recorded in 18 healthy human volunteers after instillation of boluses of SCFAs, air, and saline. Ileal motility was stimulated more often by SCFAs than by similar volumes of air or saline. Although increasing volumes of distention evoked greater numbers of contractions, this phenomenon was not apparent after repeated stimulation, suggesting that the "mechanoreceptor" in the human ileum has a refractory period. Symptoms of abdominal pain, cramps, and an urge to defecate may have resulted from instillation of SCFAs, even at small volumes. The motility stimulated in the ileum by SCFAs was not associated with systemic release of gastrointestinal regulatory peptides and was not affected by naloxone or indomethacin. Short-chain fatty acids, which can be considered as "markers" of colonic contents, might be associated with the motor response to coloileal reflux in humans.

Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study

Ethanol-induced flushing (EIF) occurs in up to 80% of Asians and is characterized by facial flushing, tachycardia, and increased cardiac output. Since endogenous opiates and prostaglandins may be mediators of flushing syndromes, we attempted to block EIF in four Asian flushers with single doses of either the opiate antagonist nalmefene, or the prostaglandin synthesis inhibitor indomethacin. Nonflushers (2 Caucasian, 2 Asian) and four Asian flushers were given on separate days water, ethanol (0.4 g/kg p.o.), ethanol plus nalmefene (2 mg i.v.), or ethanol plus indomethacin (50 mg p.o.). Ethanol concentrations of flushers and nonflushers were similar. Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001). Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion. A single dose of nalmefene (2 mg i.v.) but not indomethacin (50 mg p.o.), reduced the mean (+/- SEM) ethanol-induced rise in facial skin temperature of flushers by 58 +/- 14% (p less than 0.05) without changing plasma acetaldehyde concentrations. These data are preliminary evidence that the opiate antagonist, nalmefene, blocks some of the vascular manifestations of EIF without altering the elevated plasma concentrations of acetaldehyde.

Concentrations of cholecystokinin, substance P, and bombesin in discrete regions of male and female rat brain: sex differences and estrogen effects

The distributions of cholecystokinin, substance P, and bombesin was measured in discrete regions of the hypothalamus and limbic system in male and female rats. Higher levels of cholecystokinin immunoreactivity were determined for males compared with females during the estrous cycle in the posterior-medial aspect of the amygdaloid complex, bed nucleus of the stria terminalis, medial preoptic area, paraventricular nucleus, and ventromedial nucleus. The only region that always contained greater substance P immunoreactivity in the male was the posterior-medial amygdala. No sex differences were observed for the levels of bombesin immunoreactivity. During the estrous cycle, significantly lower levels of cholecystokinin immunoreactivity occurred during the morning of estrus in the posterior-medial amygdala, bed nucleus, median eminence, and ventromedial nucleus, whereas substance P immunoreactivity was lower on estrus in the bed nucleus and ventromedial nucleus. In the posterior-lateral aspect of the amygdala, females were observed to have more cholecystokinin immunoreactivity than males although no significant variations occurred during the estrous cycle. Bombesin-immunoreactive levels were unchanged throughout the estrous cycle in all regions assayed. In a separate experiment to test the hypothesis that estradiol enhances the release of cholecystokinin from terminals in the mediobasal hypothalamus, this region was dissected from ovariectomized and ovariectomized estrogen-primed rats and superfused with estradiol-17 beta. Indeed, exposure of the tissue to estradiol-17 beta was observed to enhance the K+-stimulated release of cholecystokinin from a mediobasal hypothalamic block in vitro. These results, as well as the variation of cholecystokinin during the estrous cycle, imply an important role for cholecystokinin in the regulation of steroid-initiated reproductive events.

Gastrointestinal neuropeptide concentrations following guanethidine sympathectomy

In an effort to investigate the interaction of the adrenergic and enteric components of the autonomic nervous system, gut neuropeptide concentrations were examined following chemical sympathectomy. Adult male rats were treated with guanethidine (40 mg/kg i.p., 5 days/week for 5 weeks), which selectively destroys peripheral sympathetic neurons. Controls received equal volumes of saline vehicle. Tissues from fundic and pyloric stomach, duodenum, jejunum, jejuno-ileum, ileum, caecum and colon were extracted and concentrations of selected neuropeptides determined by radioimmunoassay. Dopamine-beta-hydroxylase (DBH) in peripheral nerve, measured as an index of degree of sympathectomy, was depleted 80-90%. One week after cessation of treatment, vasoactive intestinal peptide (VIP) was elevated in jejunum (52%), ileum (53%), caecum (41%) and colon (59%), as was neurotensin (NT) in caecum (117%) and colon (261%). Methionine-enkephalin (MET) was lowered in duodenum by 28%. With the exception of MET in duodenum and NT in caecum, these alterations normalized by 5 weeks post-treatment, although DBH remained depressed. Statistically non-significant increases in substance P content were observed in upper gut regions. An inhibitory sympathetic input to VIPergic and NTergic systems is postulated.

Distribution of cholecystokinin-immunoreactive cell bodies in the male and female rat: II. Bed nucleus of the stria terminalis and amygdala

The distribution of cholecystokinin-immunoreactive (CCK-I) cell bodies was studied in the bed nucleus of the stria terminalis (BST) and amygdaloid complex of colchicine-treated male and female rats. Immunoreactive cells were visualized in the BST medial amygdaloid (MeA), central lateral, basolateral, basolateral ventral, medial, intercalated, anterior cortical, and posterior cortical nuclei and the amygdalohippocampal zone. Several significant sex differences were observed. In the male, a dense aggregation of CCK-I cell bodies was visualized in the MeA, especially in the dorsocaudal part and in the encapsulated part of the BST. In comparison, female rats had relatively fewer immunoreactive cells in both of these regions. In the lateral and basolateral amygdaloid nuclei, however, more CCK-I cells were visualized in the female than in the male, but the difference was not statistically significant. These data provide characterization of a sexually differentiated CCK system. In addition, we observed that the number of CCK-I cells in the BST and posterodorsal part of the MeA was substantially reduced after castration. The number of CCK-I cells in female rats, however, was not significantly reduced after ovariectomy in any of the regions studied. These findings imply that the steroid regulation of CCK is sexually differentiated. The sexually dimorphic distribution of CCK-I cells in areas that are targets of steroid hormones and regulate reproductive processes is consistent with the possibility that CCK participates in central integration of sensory and steroidal input that modulates reproductive behavior.

Idiopathic chronic constipation is associated with decreased colonic vasoactive intestinal peptide

To investigate the reported association between idiopathic chronic constipation and morphologic abnormalities of enteric nerves, we measured the concentrations of six neuropeptides, vasoactive intestinal peptide, peptide histidine-methionine, substance P, methionine5-enkephalin, neuropeptide Y, and the bombesinlike intestinal peptides, in descending colon from 4 patients with idiopathic chronic constipation. Decreased concentrations of vasoactive intestinal peptide (707 +/- 112 ng/g wet tissue) and peptide histidine-methionine (543 +/- 58 ng/g) were found in the muscularis externa obtained from constipated patients compared with normal concentrations (40 patients) of vasoactive intestinal peptide (1199 +/- 47 ng/g) and peptide histidine-methionine (815 +/- 45 ng/g). Vasoactive intestinal peptide was identified by immunocytochemistry in nerve fibers within the circular smooth muscle layer of descending colon obtained from 6 control patients, but not in nerve fibers within the circular smooth muscle of descending colon obtained from 3 patients with idiopathic chronic constipation. By contrast, the distribution of immunoreactive met5-enkephalin was similar in normal descending colon and in descending colon obtained from patients with idiopathic chronic constipation. Decreased colonic concentrations of vasoactive intestinal peptide (a candidate nonadrenergic, noncholinergic inhibitory neurotransmitter) may be associated with diminution of inhibitory innervation of colonic circular smooth muscle in some patients with idiopathic chronic constipation.

Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: sensitisation by naloxone

Cholecystokinin (CCK) has potent antinociceptive properties when given either peripherally or centrally. An interaction between opiate and CCK-induced antinociception is indicated as CCK-induced analgesia is potentiated by naloxone. Since CCK cells in Periaqueductal grey (PAG) are known to be sensitive to both noxious stimuli and i.v. morphine, the possibility that the PAG was the site of such an interaction was investigated by an in vitro study of the effects of morphine and naloxone on CCK release in PAG. The K+-evoked release of CCK from tissue slices of PAG was unaffected by a wide range of concentrations of morphine. However, after pretreatment with naloxone (10(-9) M), morphine (10(-7)-10(-6) M) caused a significant, dose dependent attenuation of CCK release (70% inhibition at 10(-6) M). These results suggest that the release of CCK in PAG is modulated by opioid systems.

Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases

To study hyperplasia of peptidergic nerves purported to be diagnostic of Crohn's disease, we determined the distribution and concentrations of gut neuropeptides in specimens of normal intestine, ulcerative colitis, and Crohn's disease. Tissue specimens obtained at surgery were dissected into the mucosal-submucosal and muscularis externa layers, and immunoreactive gut neuropeptides were acid-extracted for measurement by radioimmunoassay. The immunoreactive species were characterized by column chromatography. Mucosal-submucosal layer concentrations of vasoactive intestinal peptide were significantly decreased in Crohn's colitis and ulcerative colitis, while mucosal-submucosal layer concentrations of substance P were significantly increased in left-sided ulcerative colitis. Muscularis externa layer concentrations of vasoactive intestinal peptide and met5-enkephalin were decreased in left-sided Crohn's colitis. These neuropeptide concentration abnormalities did not clearly differentiate between Crohn's colitis and ulcerative colitis, and no increase in concentration of a neuropeptide diagnostic of Crohn's disease was identified.

Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems

Using cortical cups in chloralose-urethanized rats, the in vivo release of cholecystokinin-like immunoreactivity (CCK-LI) from cerebral cortex was examined. Resting levels of cholecystokinin-like immunoreactivity ranged from 20 to 30 pg/20 min sample. The addition of potassium (40 mM) in excess, resulted in a highly significant elevation in the levels of CCK-LI in the cortical superfusate. Deletion of calcium and the substitution of cobalt (10 mM), resulted in a significant reduction in both resting release and the release otherwise evoked by the addition of potassium. Focal electrical stimulation of the cortex (20 Hz), resulted in a significant (1.9 +/- 0.2-fold, n = 8) increase in the levels of CCK-LI. The addition of glutamate (10(-6)-10(-4) M) of kainic acid (10(-8)-10(-6) M), also resulted in significant elevations in the levels of CCK-LI. The co-administration of a putative glutamate receptor antagonist, kynurenic acid (10(-4) M) resulted in a significant reduction in the levels of release otherwise evoked by the addition of glutamate, but not by electrical stimulation. The addition of GABA (10(-5)-10(-3) M) resulted in a dose-dependent decrease in the resting release of CCK-LI, and the release evoked by glutamate. Picrotoxin (10(-6)-10(-4) M), resulted in a highly significant increase in the levels of CCK-LI in the cortical effluent. These results are consistent with a tonic GABAergic inhibition of CCK-releasing neurons. The treatment of the animal with diazepam (30 mg/kg, i.p.) also resulted in a significant reduction in resting release and the release otherwise evoked by focal cortical stimulation.

Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain

A double-label immunofluorescence technique was used to demonstrate that immunoreactivities for the functionally antagonistic neuropeptides enkephalin and cholecystokinin octapeptide (CCK) are co-localized within individual neurons and processes in discrete areas of rat midbrain and forebrain. Coexistence was most prominent within varicose pericellular axons extending from the periaqueductal gray matter to a field overlying the medial lemniscus, axons and terminal-like puncta in the central medial, paracentral, interanterodorsal and ventral anterior thalamic nuclei, and perikarya and proximal axonal fragments in layers II and III of neo- and allocortex, and in the anterior olfactory nucleus. The former two systems of axons lie in areas of spinothalamic tract termination. These data suggest that some of the antagonism of opioid analgesia by CCK occurs at the synaptic level in nociceptive areas of brain-stem and thalamus where CCK and enkephalin are co-localized and presumably co-released.

Distribution of cholecystokinin-immunoreactive cell bodies in the male and female rat: I. Hypothalamus

The hypothalamic distribution of cholecystokinin-immunoreactive (CCKI) cell bodies in colchicine-treated male and female rats was studied. Immunoreactive neurons were visualized along the anterior two-thirds of the third ventricle but were especially numerous in the preoptic periventricular nucleus. Dense aggregations of CCKI cells were found in the anterior magnocellular, posterior magnocellular, medial parvicellular, and posterior parvicellular divisions of the paraventricular nucleus. Both the supraoptic nucleus and the central, cell-dense part of the dorsomedial nucleus contained large numbers of CCKI cells. CCKI cells in the preoptic periventricular nucleus were more numerous in the female, as was a population of labeled cells in the dorsal medial preoptic area. However, CCKI cell bodies in this part of the medial preoptic area were larger in males than in females. Males had more CCKI cells in the central part of the medial preoptic nucleus and in the posterior magnocellular subdivision of the paraventricular nucleus. Both males and females had similar numbers of immunoreactive cells in the anterior magnocellular and the parvicellular divisions of the paraventricular nucleus as well as in the anterior hypothalamus, dorsal areas, dorsomedial nucleus, and supramammillary region. These data provide morphological evidence for a sexually differentiated hypothalamic CCKI system.

Septal-preoptic unit responses to microelectrophoresis of cholecystokinin, gastrin, vasoactive intestinal peptide and secretin in the rat

Effects of microelectrophoretic application of cholecystokinin-8, gastrin-17, vasoactive intestinal peptide and secretin on activities of septal-preoptic neurons were examined in ovariectomized rats. All of the 4 peptides produced either excitatory or inhibitory responses in some neurons tested. No consistent relationship was observed between effects of different peptides, even between the peptides of the same family. These results provide electrophysiologic evidence for the action in the septal-preoptic region of these peptides, and suggest that there may be specific interneurons sensitive to a corresponding peptide with some overlapping.

Increase in hypothalamic cholecystokinin following acute and chronic morphine

Recent evidence supports an antagonistic interaction between cholecystokinin (CCK) and opiate peptides. The present study determined the effects of various levels of morphine treatment on hypothalamic levels of CCK as determined by radioimmunoassay. Acute treatment with morphine sulfate (10 mg/kg) or implantation of one morphine pellet (75 mg free base) increased levels of CCK in whole hypothalamus. Increased exposure to morphine by either chronic injections or implantation of two pellets did not result in a further change in whole hypothalamic CCK levels. In samples dissected into hypothalamic subregions, the effect of morphine on CCK levels was localized to medial but not lateral or posterior regions. These experiments extend earlier in vitro findings and suggest that some of the physiological and behavioral effects of opiate peptides may result from modulation of endogenous CCK.

Effect of opiates on the release of cholecystokinin from in vitro hypothalamus and frontal cortex of Zucker lean (Fa/-) and obese (fa/fa) rats

Opiates, morphine and [D-Ala2-D-Leu5]-enkephalin (DADLE), inhibited the K+-stimulated release of cholecystokinin (CCK) from the hypothalamus of both Zucker obese (fa/fa) and lean (Fa/-) rats, in vitro. Morphine and DADLE did not inhibit the K+-stimulated release of CCK from frontal cortex from either strain. The opiates did not affect basal efflux of CCK and their effects were all blocked by equimolar concentrations of naloxone. These studies indicate a regional specificity for the effect of opiates on CCK release, and may provide evidence for a cellular mechanism by which endogenous opiates modulate feeding behavior.

Distribution and quantitation of immunoreactive gut neuropeptides in piebald mice and their normal littermates

Piebald mice inherit congenital megacolon associated with distal aganglionosis. To study the distribution of intrinsic peptidergic nerves in the gut of piebald mice and their normal littermates, we used specific radioimmunoassays to measure the tissue concentrations of the following immunoreactive neuropeptides: vasoactive intestinal peptide (VIP), peptide histidine-isoleucine (PHI), [Met]enkephalin (Enk), substance P (SP), and bombesin-like intestinal peptide (BLIP). In the normal littermates, all neuropeptide concentrations were significantly greater in the colon than in the proximal gut. SP, Enk, VIP, PHI, and BLIP levels were all decreased in the distal colon of piebald mice as compared to normal littermates, SP, BLIP, and Enk levels were also decreased in the dilated proximal colon of piebald mice. These results suggest that there are abnormalities in the peptidergic innervation of the proximal and the distal colon in piebald mice. The abnormalities localized to the proximal colon of piebald mice may be related to functional obstruction of the colon.

Comparison of substance P and enkephalin distribution in rat brain: an overview using radioimmunocytochemistry

The distribution of substance P and leucine enkephalin in mid- and fore-brain areas of the rat was studied using a radioimmunocytochemical method. The secondary antibody was labeled with 125I and the sections apposed to LKB Ultrofilm or emulsion-dipped. In alternate sections an extensive distribution of substance P and enkephalin immunoreactive material was seen in frontal, cingulate, retrosplenial, and entorhinal cortices. Substance P and enkephalin exhibited a remarkable overlap in many of these cortical areas as well as in the nucleus accumbens, caudate, portions of the hypothalamus, amygdala, thalamus and central gray. Differences in distribution were seen in the retrosplenial cortex, septum, ventromedial hypothalamus, hippocampus, the substantia nigra and the superior colliculus. The results provide a detailed immunohistochemical demonstration of the laminar patterns of substance P and enkephalin in the cortex of the rat. The results are discussed in terms of the interaction of substance P and enkephalin. The matches and mismatches of immunoreactive substance P and enkephalin and the locations of their receptors are also examined.

Potentiation of beta-endorphin effects by proglumide in rats

The effects of proglumide, a cholecystokinin (CCK) receptor antagonist, on the analgesia and catalepsy induced by beta-endorphin were investigated in rats. Proglumide itself produced a slight analgesia but no catalepsy. Combined intracerebroventricular administration of beta-endorphin and proglumide produced marked potentiation of the analgesic and cataleptic effects of beta-endorphin. The results suggest that endogenous CCK may have an antagonistic effect on the actions of beta-endorphin in the brain.

Innervation of the muscularis mucosae of canine proximal colon

The innervation of the muscularis mucosae of the canine large intestine was studied in vitro using superfusion and radioimmunological techniques. In the majority of preparations, electrical field stimulation (10 V, 200 microseconds, 10 Hz) elicited a biphasic neurogenic response which consisted of a contraction followed, after cessation of the stimulus, by relaxation. Electrical field stimulation released VIP-, substance P- and bombesin-like immunoreactivity. Release of these peptides and the biphasic response to nerve stimulation were blocked by tetrodotoxin and a 'calcium-free' solution. Several observations suggest that neuronally released substance P (or a closely related peptide) mediated the contraction by a direct action on the muscle. The contraction caused by substance P was tetrodotoxin insensitive. Desensitization to substance P abolished the excitatory response to nerve stimulation. The contraction elicited by nerve stimulation was blocked by substance P antiserum. Several observations suggest that bombesin or a closely related peptide caused contraction of the muscle by releasing substance P from intramural neurones. Bombesin caused an increase in substance P-like immunoreactivity in the superfusate which was blocked by tetrodotoxin, as was the contraction; substance P antibodies blocked the contractile response to bombesin. In addition, while the excitatory response to electrical nerve stimulation was blocked by substance P antiserum, there was still an increase in bombesin-like immunoreactivity in the superfusate. The data also suggest that VIP or a closely related peptide might have mediated the relaxation by a direct action on the muscle. The inhibitory response to nerve stimulation was mimicked by VIP and abolished by VIP antiserum.

Simultaneous measurement of cholecystokinin- and vasoactive intestinal polypeptide-like immunoreactivity from cat frontal cortex in vitro: effect of morphine and D-Ala2-D-Leu5-enkephalin

The two peptides vasoactive intestinal polypeptide (VIP) and cholecystokinin (CCK) have been demonstrated to be discretely distributed in the cerebral cortex. This distribution closely parallels the distribution of mu- and delta-opiate receptors in the frontal cortex. The basal efflux and potassium-stimulated release of VIP- and CCK-immunoreactivity was studied in the presence and absence of morphine and D-Ala2-D-Leu5-enkephalin (DADL), agents with relative affinity for the mu and delta receptors, respectively. The basal efflux of VIP- and CCK-immunoreactivity was not affected by these opiates; however, the potassium-stimulated release of VIP-immunoreactivity was profoundly inhibited in a dose-dependent manner by both morphine (ED50 = 1 X 10(-9) M) and DADL (ED50 = 3.02 X 10(-9) M). The inhibition produced by either morphine or DADL was shown to be reversed by naloxone.

Studies on the opiate receptor-mediated inhibition of K+-stimulated cholecystokinin and substance P release from cat hypothalamus in vitro

The addition of 50 mM K+ to the perfusate of cat hypothalamic slices results in a 3.4- and 5.5-fold increase in the levels of cholecystokinin (CCK) and substance P (sP) like immunoreactivity, respectively. The addition of morphine (10(-11)-10(-8) M; a mu receptor agonist) and D-Ala2-D-Leu5-enkephalin (DADL: 10(-12)-10(-10) M; a delta receptor agonist) resulted in a dose-dependent suppression of the K+-evoked release. SKF10047 (a sigma receptor ligand) and U50488H (a kappa receptor ligand) had no effect in doses up to 10(-6) M. Naloxone added with the lowest dose of agonist producing a maximal inhibition produced a dose-dependent reversal of the anti-release effects of morphine and DADL. The IC50 of naloxone for the antagonism by DADL and morphine of the release of CCK were similar, whereas the naloxone IC50 was lower for morphine than DADL in the reversal of the effects of the agonist in sP release. Within the constraints of receptor selectivity of the several ligands, these data suggest that at least two populations of opioid receptors (mu and delta) may be discriminated which govern the release of hypothalamic sP.

In vitro, release of cholecystokinin from hypothalamus and frontal cortex of Sprague-Dawley, Zucker lean (Fa/-) and obese (fa/fa) rats

Cholecystokinin (CCK) has been suggested as a putative satiety factor, whose site of action is in the hypothalamus. The genetically obese (fa/fa) Zucker rat has been proposed as a model of human obesity. Though hypothalamic tissue levels of CCK did not vary between the fa/fa rat and age-matched lean littermates (25.5 +/- 5.7 vs. 27.6 +/- 5.2 pmoles/g tissue) we sought to determine if the releasability of hypothalamic and cortical CCK was the same in lean and obese rats. The in vitro superfusion paradigm was used to study the release of CCK and substance P (sP) from hypothalamus, and CCK and vasoactive intestinal polypeptide (VIP) from frontal cortex. The potassium stimulated release of CCK from obese rat hypothalamic tissue was significantly higher than from lean rat hypothalamus (3.62 +/- 0.3 vs. 1.91 +/- 0.3 fmole equivalents CCK-8/mg tissue/10 min). Similarly, sP release was exaggerated in obese rats in a parallel fashion (5.56 +/- 0.44 vs. 2.761 +/- 0.46 fmoles/mg tissue/10 min). However, the potassium stimulated release of CCK and VIP from cortical tissue was the same in all three groups of rats. The obese Zucker rat thus, may have an anomalous release of CCK and sP from the hypothalamus, but not from the frontal cortex, an area not presumably associated with satiety.

Cholecystokinin in the central nervous system: a minireview

This review focuses on the structure, distribution, neuronal pathways, receptor binding, release, biosynthesis and degradation of CCK in the central nervous system. Other aspects of the isolation and chemistry of CCK (1), its role in satiety (2), as a hormone or neurotransmitter (3,4), and its evolution (5) have been reviewed recently.